JP2015500805A5 - - Google Patents

Download PDF

Info

Publication number
JP2015500805A5
JP2015500805A5 JP2014544885A JP2014544885A JP2015500805A5 JP 2015500805 A5 JP2015500805 A5 JP 2015500805A5 JP 2014544885 A JP2014544885 A JP 2014544885A JP 2014544885 A JP2014544885 A JP 2014544885A JP 2015500805 A5 JP2015500805 A5 JP 2015500805A5
Authority
JP
Japan
Prior art keywords
forms
double bond
individual
single bond
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014544885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500805A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/067078 external-priority patent/WO2013082292A1/en
Publication of JP2015500805A publication Critical patent/JP2015500805A/ja
Publication of JP2015500805A5 publication Critical patent/JP2015500805A5/ja
Pending legal-status Critical Current

Links

JP2014544885A 2011-11-29 2012-11-29 認知強化方法 Pending JP2015500805A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564371P 2011-11-29 2011-11-29
US61/564,371 2011-11-29
PCT/US2012/067078 WO2013082292A1 (en) 2011-11-29 2012-11-29 A method to enhance cognition

Publications (2)

Publication Number Publication Date
JP2015500805A JP2015500805A (ja) 2015-01-08
JP2015500805A5 true JP2015500805A5 (enExample) 2016-01-21

Family

ID=48536059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014544885A Pending JP2015500805A (ja) 2011-11-29 2012-11-29 認知強化方法

Country Status (8)

Country Link
US (1) US20140336184A1 (enExample)
EP (1) EP2785377A4 (enExample)
JP (1) JP2015500805A (enExample)
CN (1) CN104039353A (enExample)
AU (1) AU2012345888A1 (enExample)
CA (1) CA2856424A1 (enExample)
HK (1) HK1200085A1 (enExample)
WO (1) WO2013082292A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313428A1 (en) * 2015-06-26 2018-05-02 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
EP3383482B1 (en) 2015-11-24 2023-01-04 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
CA3044440A1 (en) 2016-11-17 2018-05-24 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
ES3058718T3 (en) 2017-10-10 2026-03-12 Massachusetts Inst Technology Systems for preventing, mitigating, and/or treating dementia
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
US20040127471A1 (en) * 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
DE112005001269T5 (de) * 2005-04-26 2008-05-29 Versitech Ltd. Polysaccharidextrakt aus Lycium barbarum als neuroprotektives Mittel gegen ß-Amyloidpeptidneurotoxizität
US20110077198A1 (en) * 2007-11-26 2011-03-31 Michael John Tisdale Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
WO2010073104A2 (en) * 2008-12-23 2010-07-01 Carmel - Haifa University Economic Corp Ltd. Improving cognitive function
CN102647904A (zh) * 2009-09-16 2012-08-22 赛林药物股份有限公司 新型三环蛋白激酶调节剂

Similar Documents

Publication Publication Date Title
JP2009535462A5 (enExample)
JP2011518833A5 (enExample)
JP2006526031A5 (enExample)
JP2010501534A5 (enExample)
JP2007269812A5 (enExample)
JP2009545527A5 (enExample)
JP2009530282A5 (enExample)
JP2007522220A5 (enExample)
JP2009502793A5 (enExample)
JP2010095546A5 (enExample)
JP2013032389A5 (enExample)
JP2014500861A5 (enExample)
JP2010530897A5 (enExample)
JP2018531941A5 (enExample)
JP2010536889A5 (enExample)
JP2009149903A5 (enExample)
JP2014515013A5 (enExample)
JP2010520851A5 (enExample)
JP2011500769A5 (enExample)
JP2013532130A5 (enExample)
JP2013539454A5 (enExample)
CN112074519A8 (zh) 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征(ibs)的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
JP2019059781A5 (enExample)
JP2017511377A5 (enExample)
JP2010521516A5 (enExample)